{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:28:56Z","timestamp":1792290536816,"version":"4.4.0"},"reference-count":42,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002457","name":"Chosun University","doi-asserted-by":"publisher","award":["2024"],"award-info":[{"award-number":["2024"]}],"id":[{"id":"10.13039\/501100002457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["IJMS"],"abstract":"<jats:p>YTHDF1, an N6-methyladenosine (m6A)-binding protein, plays a key role in breast cancer progression, yet its therapeutic targeting remains underexplored. In this study, we investigated the anticancer effects of the novel YTHDF1 inhibitor ebselen in breast cancer cells. Ebselen treatment reduced cell viability in a dose-dependent manner and induced apoptosis, as demonstrated by Annexin V staining, Sub-G1 accumulation, and DNA fragmentation. Consistently, ebselen increased reactive oxygen species (ROS) production and impaired autophagy induction. Mechanistically, ebselen impaired YTHDF1-mediated stabilization and translation of FOS mRNA, leading to decreased c-Fos expression. In addition, ebselen suppressed anchorage-independent growth in vitro and significantly reduced tumor growth in an orthotopic mouse model. These findings highlight YTHDF1 as a promising therapeutic target and support ebselen as a potential small-molecule inhibitor for breast cancer treatment.<\/jats:p>","DOI":"10.3390\/ijms26199416","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:33:03Z","timestamp":1758889983000},"page":"9416","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ebselen Suppresses Breast Cancer Tumorigenesis by Inhibiting YTHDF1-Mediated c-Fos Expression"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-2374","authenticated-orcid":false,"given":"Arathy","family":"Vasukutty","sequence":"first","affiliation":[{"name":"Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poshan Yugal","family":"Bhattarai","sequence":"additional","affiliation":[{"name":"Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7862-2342","authenticated-orcid":false,"given":"Hong Seok","family":"Choi","sequence":"additional","affiliation":[{"name":"Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"\u0141ukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., and Stanis\u0142awek, A. (2021). Breast cancer\u2014Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014An updated review. Cancers, 13.","DOI":"10.3390\/cancers13174287"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Burguin, A., Diorio, C., and Durocher, F. (2021). Breast cancer treatments: Updates and new challenges. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080808"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Duan, S., and Buxton, I.L. (2022). Evolution of medical approaches and prominent therapies in breast cancer. Cancers, 14.","DOI":"10.3390\/cancers14102450"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lau, K.H., Tan, A.M., and Shi, Y. (2022). New and emerging targeted therapies for advanced breast cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042288"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"755053","DOI":"10.3389\/fonc.2022.755053","article-title":"Evolution of molecular targeted cancer therapy: Mechanisms of drug resistance and novel opportunities identified by CRISPR-Cas9 screening","volume":"12","author":"Hou","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"113621","DOI":"10.1016\/j.ejmech.2021.113621","article-title":"Small molecule selenium-containing compounds: Recent development and therapeutic applications","volume":"223","author":"Chuai","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Radomska, D., Czarnomysy, R., Szymanowska, A., Radomski, D., Dom\u00ednguez-\u00c1lvarez, E., Bielawska, A., and Bielawski, K. (2022). Novel selenoesters as a potential tool in triple-negative breast cancer treatment. Cancers, 14.","DOI":"10.3390\/cancers14174304"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1002\/mco2.181","article-title":"Small molecule inhibitors targeting the cancers","volume":"3","author":"Liu","year":"2022","journal-title":"MedComm"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Debnath, S., Agarwal, A., Kumar, N.R., and Bedi, A. (2022). Selenium-based drug development for antioxidant and anticancer activity. Future Pharmacol., 2.","DOI":"10.3390\/futurepharmacol2040036"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100844","DOI":"10.1016\/j.drup.2022.100844","article-title":"Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents","volume":"63","author":"Nasim","year":"2022","journal-title":"Drug Resist. Updates"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0891-5849(93)90028-S","article-title":"Ebselen, a selenoorganic compound as glutathione peroxidase mimic","volume":"14","author":"Sies","year":"1993","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1007\/s11033-014-3417-x","article-title":"Ebselen, a promising antioxidant drug: Mechanisms of action and targets of biological pathways","volume":"41","author":"Azad","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Park, W.H. (2023). Ebselen Inhibits the Growth of Lung Cancer Cells via Cell Cycle Arrest and Cell Death Accompanied by Glutathione Depletion. Molecules, 28.","DOI":"10.3390\/molecules28186472"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"da Costa, N.S., Lima, L.S., Oliveira, F.A.M., Galiciolli, M.E.A., Manzano, M.I., Garlet, Q.I., Irioda, A.C., and Oliveira, C.S. (2023). Antiproliferative Effect of Inorganic and Organic Selenium Compounds in Breast Cell Lines. Biomedicines, 11.","DOI":"10.3390\/biomedicines11051346"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1021\/acsptsci.2c00008","article-title":"Small-molecule Ebselen binds to YTHDF proteins interfering with the recognition of N 6-Methyladenosine-modified RNAs","volume":"5","author":"Micaelli","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41419-022-04672-5","article-title":"YTHDF1 promotes breast cancer cell growth, DNA damage repair and chemoresistance","volume":"13","author":"Sun","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41419-022-04711-1","article-title":"YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis","volume":"13","author":"Yao","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/gutjnl-2022-328845","article-title":"Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer","volume":"72","author":"Bao","year":"2023","journal-title":"Gut"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"607224","DOI":"10.3389\/fonc.2021.607224","article-title":"YTHDF1 is a potential pan-cancer biomarker for prognosis and immunotherapy","volume":"11","author":"Hu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12272-023-01480-z","article-title":"The PIN1-YTHDF1 axis promotes breast tumorigenesis via the m6A-dependent stabilization of AURKA mRNA","volume":"47","author":"Shrestha","year":"2024","journal-title":"Arch. Pharmacal Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13578-022-00759-w","article-title":"YTHDF1 promotes breast cancer progression by facilitating FOXM1 translation in an m6A-dependent manner","volume":"12","author":"Chen","year":"2022","journal-title":"Cell Biosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"217047","DOI":"10.1016\/j.canlet.2024.217047","article-title":"YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation","volume":"597","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.ejca.2005.08.008","article-title":"The Fos family of transcription factors and their role in tumourigenesis","volume":"41","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1038\/sj.onc.1208905","article-title":"cFos is critical for MCF-7 breast cancer cell growth","volume":"24","author":"Lu","year":"2005","journal-title":"Oncogene"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e53211","DOI":"10.1371\/journal.pone.0053211","article-title":"Old Players with a Newly Defined Function: Fra-1 and c-Fos Support Growth of Human Malignant Breast Tumors by Activating Membrane Biogenesis at the Cytoplasm","volume":"8","author":"Motrich","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12681","DOI":"10.1093\/nar\/gkx865","article-title":"Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone","volume":"45","author":"Enuka","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41420-023-01321-4","article-title":"The potential role of m6A reader YTHDF1 as diagnostic biomarker and the signaling pathways in tumorigenesis and metastasis in pan-cancer","volume":"9","author":"Zhu","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/cac2.12407","article-title":"Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancer","volume":"43","author":"Keelan","year":"2023","journal-title":"Cancer Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.2147\/CMAR.S254853","article-title":"Discovery of Ebselen as an Inhibitor of 6PGD for Suppressing Tumor Growth","volume":"12","author":"Feng","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lv, C., Zeng, Q., Qi, L., Wang, Y., Li, J., Sun, H., Du, L., Hao, S., Li, G., and Feng, C. (2024). Sodium Selenite Induces Autophagy and Apoptosis in Cervical Cancer Cells via Mitochondrial ROS-Activated AMPK\/mTOR\/FOXO3a Pathway. Antioxidants, 13.","DOI":"10.3390\/antiox13081004"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13578-022-00944-x","article-title":"Discovery and mechanism studies of a novel ATG4B inhibitor Ebselen by drug repurposing and its anti-colorectal cancer effects in mice","volume":"12","author":"Xie","year":"2022","journal-title":"Cell Biosci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41571-023-00774-x","article-title":"The roles and implications of RNA m6A modification in cancer","volume":"20","author":"Deng","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1490740","DOI":"10.3389\/fonc.2024.1490740","article-title":"Selenium in cancer management: Exploring the therapeutic potential","volume":"14","author":"He","year":"2025","journal-title":"Front. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e31216","DOI":"10.1002\/jcp.31216","article-title":"Role of c-Fos in DNA damage repair","volume":"239","author":"Yao","year":"2024","journal-title":"J. Cell. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2020.01.033","article-title":"METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification","volume":"20","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41422-018-0092-9","article-title":"METTL3-mediated N6-methyladenosine mRNA modification enhances long-term memory consolidation","volume":"28","author":"Zhang","year":"2018","journal-title":"Cell Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","article-title":"N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency","volume":"161","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/0008-5472.CAN-23-1916","article-title":"N6-Methyladenosine Reader YTHDF1 Promotes Stemness and Therapeutic Resistance in Hepatocellular Carcinoma by Enhancing NOTCH1 Expression","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"852424","DOI":"10.3389\/fonc.2022.852424","article-title":"Crosstalk Between ROS and Autophagy in Tumorigenesis: Understanding the Multifaceted Paradox","volume":"12","author":"Hasan","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cpan.2024.12.002","article-title":"Advances in drug discovery based on network pharmacology and omics technology","volume":"21","author":"Liu","year":"2024","journal-title":"Curr. Pharm. Anal."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41388-023-02617-6","article-title":"METTL3 stabilization by PIN1 promotes breast tumorigenesis via enhanced m6A-dependent translation","volume":"42","author":"Bhattarai","year":"2023","journal-title":"Oncogene"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9416\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:33:23Z","timestamp":1758890003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":42,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26199416"],"URL":"https:\/\/doi.org\/10.3390\/ijms26199416","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}